UK markets close in 4 hours 59 minutes
  • FTSE 100

    +113.58 (+1.44%)
  • FTSE 250

    +173.46 (+0.89%)
  • AIM

    +2.67 (+0.36%)

    -0.0025 (-0.22%)

    -0.0031 (-0.25%)
  • Bitcoin GBP

    +929.98 (+1.77%)
  • CMC Crypto 200

    +18.53 (+1.32%)
  • S&P 500

    -43.89 (-0.88%)
  • DOW

    +211.00 (+0.56%)

    -0.33 (-0.40%)

    -40.30 (-1.67%)
  • NIKKEI 225

    +370.26 (+1.00%)

    +287.55 (+1.77%)
  • DAX

    +125.32 (+0.71%)
  • CAC 40

    +26.95 (+0.34%)

Here's Why We're Watching CureVac's (NASDAQ:CVAC) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

Given this risk, we thought we'd take a look at whether CureVac (NASDAQ:CVAC) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.

Check out our latest analysis for CureVac

When Might CureVac Run Out Of Money?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. As at September 2023, CureVac had cash of €464m and no debt. In the last year, its cash burn was €335m. That means it had a cash runway of around 17 months as of September 2023. Importantly, analysts think that CureVac will reach cashflow breakeven in 4 years. That means unless the company reduces its cash burn quickly, it may well look to raise more cash. The image below shows how its cash balance has been changing over the last few years.


How Well Is CureVac Growing?

We reckon the fact that CureVac managed to shrink its cash burn by 37% over the last year is rather encouraging. But it makes us pessimistic to see that operating revenue slid 56% in that time. Considering both these factors, we're not particularly excited by its growth profile. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Easily Can CureVac Raise Cash?

Even though it seems like CureVac is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.


Since it has a market capitalisation of €744m, CureVac's €335m in cash burn equates to about 45% of its market value. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising.

So, Should We Worry About CureVac's Cash Burn?

Even though its falling revenue makes us a little nervous, we are compelled to mention that we thought CureVac's cash burn reduction was relatively promising. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. Taking an in-depth view of risks, we've identified 3 warning signs for CureVac that you should be aware of before investing.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.